BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacol Res 2023;187:106568. [PMID: 36423787 DOI: 10.1016/j.phrs.2022.106568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother 2023;160:114392. [PMID: 36804123 DOI: 10.1016/j.biopha.2023.114392] [Reference Citation Analysis]
2 Mirabedini S, Musavi H, Makhlough A, Hashemi-Sooteh MB, Zargari M. Association of S19W polymorphism in APOA5 gene and serum lipid levels in patients with type 2 diabetic nephropathy. Horm Mol Biol Clin Investig 2023. [PMID: 36855913 DOI: 10.1515/hmbci-2022-0056] [Reference Citation Analysis]
3 Sung WJ, Hong J. Targeting lncRNAs of colorectal cancers with natural products. Front Pharmacol 2022;13:1050032. [PMID: 36699052 DOI: 10.3389/fphar.2022.1050032] [Reference Citation Analysis]